Loading clinical trials...

RECRUITINGPHASE1

A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes

A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 Injection at Steady State in Subjects With Type 2 Diabetes

NCT07032688•Jiangsu HengRui Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

The objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of SHR-3167 at steady state in subjects with type 2 diabetes.

Eligibility

Age

18 - 59 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Informed consent obtained before any trial-related activities.
•2. Age 18\~59 years at screening (including cut-off values at both ends).
•3. Confirmed diagnosis of type 2 diabetes mellitus ≥ 6 months before screening.
•4. Female subjects of childbearing potential and their partners are male subjects of childbearing potential, who have no fertility plan and agree to take high-efficiency contraceptive measures within 3 months after signing the informed consent form and have no plans to donate eggs/sperm; Female subjects of childbearing potential have a negative pregnancy test during the screening period and are not lactating.

Exclusion Criteria

•1. Poor blood pressure control at screening.
•2. Known or suspected allergy to investigational drug products or related products; or a history of multiple and/or severe allergies to drugs or foods.
•3. Serious cardiovascular and cerebrovascular diseases within 6 months prior to screening.
•4. Positive test for hepatitis B surface antigen (HBsAg), HIV antibody, treponema pallidum specific antibody, or hepatitis C virus antibody; or the investigator judges that the subject is in the incubation or active phase of the above infection.
•5. Malignancy or history of malignancy within 5 years prior to screening.
•6. Participation in any clinical trial of an approved or unapproved investigational drug/medical device within 90 days prior to screening.
•7. Any other condition judged by the investigator to be likely to affect the subject's safety or interfere with the evaluation of trial results.

Locations (1)

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Key Dates

Start Date

August 11, 2025

Primary Completion Date

March 1, 2027

Completion Date

April 1, 2027

Last Updated

September 10, 2025

Enrollment

ESTIMATED participants

Conditions

Type 2 Diabetes

Interventions

SHR-3167 Injection

DRUG

Insulin Degludec Injection

DRUG

Contacts

Han Jianting

CONTACT

+86-0518-82342973 jianting.han.jh27@hengrui.com

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGPHASE2

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484

Type 2 DiabetesCortisol Excess

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 10, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes

Closed-loop in Adults With Type 2 Diabetes

SGLT2i, Pioglitazone, and Ketone Production in T2D